BDSX
Biodesix, Inc.7.90
+0.38+5.05%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details seasonality, rep ramps
Q&A largely reaffirmed the scripted story, detailing expected Q1 volume and ASP step-downs matching historical seasonality, plus weather hits. Primary care drove 12% of Nodify tests, up 67% YoY, with teams eager for more. Reps ramp in two to three months. Cash feels solid; no dilution needed. Pipeline stays pre-commercial—no launches in 12 months—to prioritize profitability. Analysts flagged step-downs and data timelines; management stayed qualitative on stage shift evidence. Steady tone signals sales tenure as key watch.
Key Stats
Market Cap
63.20MP/E (TTM)
-Basic EPS (TTM)
-5.23Dividend Yield
0%Recent Filings
8-K
Q4 revenue surges 41%
Biodesix crushed Q4 2025 with $28.8M revenue, up 41% year-over-year, 83% gross margin, and first-ever Adjusted EBITDA positivity at $0.5M. Full-year revenue hit $88.5M, beating guidance, while net loss improved 52% to $4.0M. Cash stands at pro forma $33.7M post-ATM; guides FY2026 revenue to $106-112M. Debt extended to 2028.
10-K
FY2025 results
Biodesix delivered FY2025 revenue of $88.5 million, up 24% y/y, with Lung Diagnostic Testing at $79.2 million (22% y/y growth from 62,600 tests, up 15%) and Development Services surging 41% to $9.3 million. Q4 accelerated sharply: core organic Diagnostic revenue hit $24.1 million (40% y/y), fueled by 23% test volume gains and higher average revenue per test from payer wins and revenue cycle tweaks; gross margins expanded to 81% annually (up 300bps) and 83% in Q4 via workflow efficiencies. Operating expenses rose just 10% y/y to $99.7 million despite revenue surge, trimming net loss to $35.3 million (18% improvement). Year-end cash stood at $19.0 million, bolstered by $33.7 million pro forma including ATM proceeds; debt extended to 2028. Supply disruptions from single-source vendors threaten quarterly momentum.
10-Q
Q3 FY2025 results
Biodesix posted Q3 revenue of $21.8M, up 20% y/y from $18.2M, with diagnostic tests at $19.8M (up 16% y/y) and development services nearly doubling to $1.9M. Operating loss narrowed to $7.1M from $8.6M y/y while net loss improved 15% to $8.7M, as gross margins hit 81% amid workflow tweaks. Cash dipped to $16.6M after drawing $10M on its Perceptive term loan (now $50M total, due 2027 at ~13%); ATM raised $4.8M net. Reverse split regained Nasdaq compliance. Yet single-source suppliers pose supply risks.
8-K
Q3 revenue up 20%
Biodesix posted Q3 revenue of $21.8 million, up 20% from last year, with Lung Diagnostic Testing at $19.8 million (up 16%) and Development Services surging 97% to $1.9 million. Gross margins hit 81%, up 400 basis points, yet operating expenses rose 10% on sales expansion. Raised FY2025 revenue guidance to $84-86 million. Cash burn continues.
8-K
Biodesix regains Nasdaq compliance
Biodesix regained Nasdaq compliance on September 26, 2025, after its common stock closed above $1.00 per share for ten consecutive business days, resolving a March 24, 2025, deficiency notice. This lifts the delisting threat, stabilizing the company's market position. Compliance restored. No further actions required.
IPO
Website
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
196.39-3.70
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CODX
Co-Diagnostics, Inc.
0.25-0.02
DGX
Quest Diagnostics Incorporated
178.66-5.45
EXAS
Exact Sciences Corporation
101.76+0.02
IDXG
Interpace Biosciences, Inc.
1.14-0.02
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
LH
Labcorp Holdings Inc.
258.11-5.22
PSNL
Personalis, Inc.
7.98-0.50
VCYT
Veracyte, Inc.
43.22-0.31